Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
HIMS Holdings filed a Form 144 notice reporting proposed sales of Class A shares by an affiliate and by Michael Y. Chi. The filing lists 14,027 Class A shares associated with Fidelity Brokerage Services and a separate entry showing 97,289 Class A shares tied to Michael Y. Chi, with transaction dates in 06/15/2026 and 03/17/2026.
The entry for the Fidelity line includes an amount of $441,850.50 and a date of 06/17/2026; Michael Y. Chi's row shows $2,402,065.41. The securities are listed as resulting from Restricted Stock Vesting and the filer is identified as the Issuer.
HIMS Holdings Inc. notice indicates proposed sales of Class A shares through Fidelity Brokerage Services. The excerpt lists scheduled restricted stock vesting events for Class A shares on 06/15/2025 (712 shares), 09/15/2025 (706 shares) and 03/15/2026 (6,155 shares). The record shows an individual, Irene Becklund, with a reported sale of 5,529 Class A shares on 03/17/2026 for $136,511.01.
Hims & Hers Health director David B. Wells exercised stock units granted as board compensation and received additional common shares. On June 11, 2026 he converted 3,656 Restricted Stock Units into Class A Common Stock, and on June 15, 2026 he converted another 957 units, for a total of 4,613 shares. These RSUs were issued under the company’s Director Compensation Policy in lieu of $22,000 of cash fees, based on a grant price of $22.98 per unit. After these routine compensation-related transactions, Wells directly holds 229,030 shares of Class A Common Stock.
Hims & Hers Health director Kare Schultz exercised restricted stock units to acquire additional shares of Class A common stock. On June 11, 2026, 3,656 RSUs were converted into 3,656 shares of Class A common stock at a stated price of $0.00 per share. After this derivative exercise, Schultz directly owns 19,397 shares of Class A common stock. The RSUs represent a contingent right to receive one share of Class A common stock for each unit, subject to continuous service and vesting on the earlier of the 2026 annual meeting of stockholders or June 15, 2026.
Hims & Hers Health director Andrea G Perez Garcia exercised restricted stock units into common shares. On June 11, 2026, 3,656 Restricted Stock Units were converted into 3,656 shares of Class A Common Stock at a per-share price of $0.00.
Following this compensation-related transaction, Perez Garcia held 83,822 shares of Class A Common Stock directly. The footnote explains that the RSUs represent a right to receive one Class A share per unit and, subject to continuous service, will vest on the earlier of the 2026 annual meeting of stockholders or June 15, 2026.
Hims & Hers Health Chief Medical Officer Patrick Harrison reported routine equity compensation activity. On June 11 and June 15, 2026, he exercised Restricted Stock Units (RSUs) to acquire a total of 4,091 shares of Class A Common Stock at a conversion price of $0.00 per share, with the corresponding RSU derivative positions reduced to zero.
Following these transactions, Harrison directly owned 187,971 shares of Class A Common Stock, which includes 1,440 shares acquired on May 20, 2026 under the company’s 2020 Employee Stock Purchase Plan. Footnotes explain that RSUs represent the right to receive one share of Class A Common Stock for each unit and that a prior RSU grant was calculated by dividing foregone cash fees of $10,000 by a grant price of $22.98.
Hims & Hers Health, Inc. Chief Policy Officer Deborah M. Autor exercised restricted stock units that converted into 3,656 shares of Class A Common Stock on June 11, 2026 at no cost. These RSUs each represented a right to receive one share upon vesting. Following the transaction, she directly holds 31,438 Class A shares, and no shares were sold in this filing.
Hims & Hers Health, Inc. filed an initial Form 3 for board member Amoo-Gottfried Kofi Owusu, indicating his status as a director but not as an officer or ten percent owner. The filing does not report any insider transactions or derivative positions and serves mainly as an initial ownership disclosure.
Hims & Hers Health, Inc. director Christopher D. Payne exercised restricted stock unit awards into a total of 14,343 shares of Class A Common Stock in June 2026, all at a price of $0.00 per share. These are compensation-related derivative exercises rather than open‑market purchases or sales.
After the transactions, he holds 34,318 shares directly and 110,000 shares indirectly through The Payne Family Trust dated September 17, 2020. Some RSUs remain outstanding, including 10,040 units granted in lieu of $14,875 of first‑quarter 2026 director and committee cash fees, calculated at a grant price of $22.98 per share and scheduled to vest on the company’s next quarterly vesting date.